MYR PHARMA
MYR Pharma is a biotech company specializing in the treatment of hepatitis B and D.
Similar Organizations
Current Employees Featured
Investors List
JOINT JOURNEY
JOINT JOURNEY investment in Venture Round - MYR Pharma
Official Site Inspections
http://www.myr-pharma.com Semrush global rank: 6.48 M Semrush visits lastest month: 973
Unable to get host informations!!!
More informations about "MYR Pharma"
MYR Pharmaceuticals - Overview, News & Similar companies
Feb 21, 2022 · MYR Pharmaceuticals contact info: Phone number: +49 5139894379 Website: www.myr-pharma.com What does MYR Pharmaceuticals do? MYR Pharmaceuticals is a …See details»
MYR GmbH - Crunchbase Company Profile & Funding
MYR is a biotechnology company developing and commercilizing therapeutics for the treatment of chronic hepatitis B and D infections. View contacts for MYR GmbH to access new leads and connect with decision-makers.See details»
Gilead Sciences Completes Acquisition of MYR GmbH
Mar 4, 2021 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MYR …See details»
MYR Pharma - Crunchbase Company Profile & Funding
MYR Pharma is a biotech company specializing in the treatment of hepatitis B and D.See details»
MYR Pharmaceuticals Company Profile 2024: Valuation, …
Operator of a commercial-stage biotechnology company focused on the treatment of hepatitis B and D.See details»
MYR Pharmaceuticals - Overview, News & Competitors - ZoomInfo
MYR Pharmaceuticals. Drug Stores & Pharmacies · Germany · <25 Employees . MYR Pharma is focused on the development of Myrcludex B, a first-in-class entry inhibitor for treatment of …See details»
Gilead Sciences to Acquire MYR GmbH
Dec 10, 2020 · MYR started operations in 2011 and has been supported by its founders, private and venture capital investors including the High-Tech-Gründerfonds (www.htgf.de/en/). For …See details»
MYR Pharmaceuticals - Craft
MYR Pharmaceuticals is a biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B (HBV) and D (HDV) …See details»
MYR Pharmaceuticals (MYR GmbH) - startbase.com
Biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis infections.See details»
MYR Pharma - Crunchbase
MYR Pharma is a biotech company specializing in the treatment of hepatitis B and D.See details»
Gilead Sciences to Acquire MYR GmbH - PR Newswire
Dec 10, 2020 · FOSTER CITY, Calif. and BAD HOMBURG, Germany, Dec. 10, 2020 /PRNewswire/ -- Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH, a German …See details»
Gilead snaps ups German virology biotech MYR, nabbing a …
Dec 10, 2020 · Well, no: The speedy authorization of remdesivir in COVID-19 saw its infectious disease credentials reinstated this year, and, now, it’s doubling down with a deal to buy out …See details»
After leading MYR to $1.5B exit via Gilead, finance chief Christély ...
Aug 19, 2021 · After helping lead MYR Pharmaceuticals to a €1.15 billion exit to Gilead Sciences last December, Thomas Christély is ready for his next challenge as the new CEO of …See details»
Bulevirtide: First Approval | Drugs - Springer
Sep 14, 2020 · Bulevirtide (Hepcludex ®), a first-in-class entry inhibitor, is being developed by MYR GmbH for the treatment of chronic hepatitis delta virus (HDV) and chronic hepatitis B …See details»
MYR Pharmaceuticals (MYR GmbH) - Startbase
Biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis infections.See details»
MYR Pharma - Funding, Financials, Valuation & Investors
MYR Pharma is a biotech company specializing in the treatment of hepatitis B and D.See details»
The Carbon Impact of Biotech & Pharma: Crossing the Tipping …
Nov 13, 2024 · The biotech and pharma industry plays a pivotal role in advancing global health, but as a significant contributor to climate change, its environmental footprint cannot be …See details»
Adragos Pharma acquires Baccinex | The Pharmaletter
7 hours ago · Munich, Germany headquartered contract development and manufacturing organization (CDMO) Adragos Pharma has acquired Baccinex, a Swiss-based expert in …See details»
A giant planet transiting a 3-Myr protostar with a misaligned disk
Nov 20, 2024 · Fig. 1: TESS light curve of IRAS 04125+2902. Pebble accretion models can form and migrate a solid core of about tens of Earth masses to <0.2 AU within 2–3 Myr (ref. 16). …See details»
MYR Pharma - Contacts, Employees, Board Members, Advisors
MYR Pharma is a biotech company specializing in the treatment of hepatitis B and D.See details»